Welcome to LookChem.com Sign In|Join Free
  • or
tert-butyl 2-chloro-4-hydroxyphenylcarbamate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

201811-58-7

Post Buying Request

201811-58-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

201811-58-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 201811-58-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,1,8,1 and 1 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 201811-58:
(8*2)+(7*0)+(6*1)+(5*8)+(4*1)+(3*1)+(2*5)+(1*8)=87
87 % 10 = 7
So 201811-58-7 is a valid CAS Registry Number.

201811-58-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name (2-chloro-4-hydroxy-phenyl)carbamic acid tert-butyl ester

1.2 Other means of identification

Product number -
Other names (2-chloro-4-hydroxy-phenyl)carbamic acid tert-butyl ester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:201811-58-7 SDS

201811-58-7Relevant academic research and scientific papers

POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES

-

Page/Page column 131, (2021/01/29)

The current invention provides urea derivatives, in particular compounds having the core structure heteroaryl-NH-CO-NH-aryl-O- heteroaryl, for use in treating, ameliorating, delaying, curing and/ or preventing a disease or condition associated with muscle cells and/or satellite cells, such as Duchenne muscular dystrophy, Becker muscular dystrophy, cachexia or sarcopenia.

Isotope enrichment lenvatinib

-

Paragraph 0074, (2020/03/09)

The invention discloses isotope enrichment lenvatinib, a pharmaceutically acceptable salt form thereof, and a treatment method using the isotope enrichment lenvatinib, and specifically relates to an isotope enrichment compound represented by a formula I o

Tert-Butyl(3-cyano-4,6-dimethylpyridin-2-yl)carbonate as a green and chemoselective N-tert-butoxycarbonylation reagent

Du, Fangyu,Zhou, Qifan,Fu, Yang,Zhao, Hanqi,Chen, Yuanguang,Chen, Guoliang

supporting information, p. 6549 - 6554 (2019/05/04)

The use of tert-butyl(3-cyano-4,6-dimethylpyridin-2-yl)carbonate as a chemoselective tert-butoxycarbonylation reagent for aromatic and aliphatic amines has been demonstrated. To gain insight into this reaction, in situ React IR technology was used to confirm the effectivity and chemoselectivity of this novel Boc reagent. The reaction was carried out chemoselectively in high yield under mild, environment-friendly conditions and was completed quickly within 1 hour. Simultaneously, the Boc carrier was easily recyclable, and has great application prospects for industrial production.

Synthetic method of anti-cancer drug lenvatinib

-

Paragraph 0112; 0137; 0138; 0173; 0174; 0208; 0209; 0244, (2018/04/02)

The invention discloses a synthetic method of anti-cancer drug lenvatinib. Lenvatinib is synthesized from the compound p-aminosalicylic acid shown as drawing 1 as a starting material with the method.Reaction conditions are mild, special reaction equipment is not needed, and the applicable range is wider. Raw materials and reagents used in the method are easily purchased from the market, and reduction of production cost is facilitated. The method is simple to operate, short in synthesis period and more suitable for large-scale industrial production of lenvatinib. The method is high in synthesis efficiency, and purity of synthesized lenvatinib is high.

A method for preparing le Fati Nepal

-

Paragraph 0077; 0078; 0079, (2017/08/25)

The invention discloses a preparation method of lenvatinib. The preparation method comprises the following steps : adopting 4-amino-3-irgasan as a starting material, firstly adopting amino groups for protection, then carrying out butt jointing with 4-chloro-7-methoxyquinoline-6-amide, removing amino-group protective groups, reacting with cyclopropylamine and preparing to obtain the lenvatinib. The preparation method disclosed by the invention is simple and easy to implement, high in yield, good in quality and convenient in industrial production.

CYCLIC AMIDE DERIVATIVE

-

Paragraph 1241, (2013/08/15)

[Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogues and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of solving the problem] A compound of Formula (1): (where n is 0 to 2; p is 0 to 4; h is 0 to 3; j is 0 to 3; k is 0 to 2; a ring B is an aryl group or a heteroaryl group; X is O, S, or —NR7—; J1 is —CR11aR11b— or —NR11c—; J2 is —CR12aR12b— or —NR12c—; and R1 to R12c are specific groups), a salt of the compound, or a solvate of the salt or the compound.

INHIBITORS OF ACETYL-COA CARBOXYLASE

-

Page/Page column 64, (2010/11/17)

The present invention relates to compounds that act as acetyl-CoA carboxylase (ACC) inhibitors. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.

NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME

-

Page/Page column 48, (2008/06/13)

The present invention relates to compounds of formula (I), which inhibit acetyl-CoA carboxylase (ACC) and are useful for the prevention or treatment of metabolic syndrome, type II diabetes, obesity, atherosclerosis and cardiovascular diseases in humans.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 201811-58-7